Increasing Prevalence of Xerostomia and Upsurge in Initiatives by Market Players Drive the Growth of the Xerostomia Therapeutics Market

Xerostomia is a disorder of dry mouth. It is an illness where the salivary glands fail their capacity to generate the anticipated result of saliva in the mouth. But this isn’t the sole cause. Xerostomia may happen even in incidences of not in taking necessary fluids, sleeping with mouth open, revealing the body alongside hot weather for a long time, medicine side effects etc. Circumstances like diabetes and HIV aids can have an influence on the salivary glands. Thus, this can also lead to xerostomia. Menopause is additional reason in women that can lead to xerostomia.

Chemotherapy and radiation harm the salivary gland and results in dry mouth. Chemotherapy is the most common form of treatment to cancer patients provided by oncologists and medical practitioners. According to the Centers for Disease Control & Prevention (CDC), each year around 650,000 cancer patients take chemotherapy in an outpatient oncology clinic. The American Cancer Society evaluates that 3.5 million women live with breast cancer in the U.S., as of January 1, 2016. Among women with stage IV breast cancer, 48% accept radiation and/or chemotherapy.

Click Here to Access the Free Sample Report @ 

Easy obtainability of cost-effective medicines is among the key drivers of the market. Products comprise saliva substitute gels, mouthwashes & oral rinses, sugar-free chewing gums, lozenges, toothpastes & oral-adhering discs, patches, and melts. The price of these products range from USD 10 to 90 and the reimbursement strategies of these products are favourable. For example, Ontario Ministry of Health and Long-Term Care provides funds to patients with radiation-induced xerostomia enduring treatment with drug, Salagen, in the Exceptional Access Program (EAP).

The global demand for xerostomia therapeutics market was predicted to be about USD 600 million in 2022, and by the end of 2031, existing and expected developments would hit valuations of around USD 1,000 million. The industry players and analysts predict the global Xerostomia therapeutics market growth of around 3.5% in terms of CAGR. During the upcoming years, the rising adoption of chemotherapy and radiotherapy in cancer treatment coupled with increasing use of prescribed medications are some of the key factors projected to drive the market. Increase in the patients with diabetes around the globe impact the salivary glands. Also, consuming medicines can have a range of side effects where one of them is dry mouth. Therefore, people liable more and more and medicines are in a way backing to the growth of the xerostomia therapeutics market. Growing creativity and consciousness of the same is also endorsing the growth of the market. On the other hand, finger-prick autologous blood treatment, along with low level of awareness about the same in undersized nations can be a restraint in the growth of this market.

Some of the leading and top xerostomia therapeutics companies in the global xerostomia therapeutics market include GlaxoSmithKline PLC, Parnell Pharmaceuticals Inc., Bausch Health Companies Inc., 3M, Quest Products Inc., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals PLC, Lupin Limited, Sun Pharmaceutical Industries Ltd, Sanofi (Chattem, Inc.), Synedgen Inc. (Prisyna), ADVANZ PHARMA Corp. Limited, Saliwell Ltd, Pharmascience Inc (Pendopharm) among others. The leading five players such as GlaxoSmithKline PLC, Parnell Pharmaceuticals Inc., Bausch Health Companies Inc., 3M, and Quest Products Inc. hold about 40% market share of the global xerostomia therapeutics market.

On the basis of type, the global xerostomia therapeutics market can be segmented into artificial saliva/saliva substitutes and salivary stimulants with the ‘artificial saliva/saliva substitutes’ category having the leading market share of about 60 percent, closely followed by the “salivary stimulants” category at about 40 percent of the global xerostomia therapeutics market share. On the basis of product, the global xerostomia therapeutics market can be segmented into drugs, salivary pens, and other product types. On the basis of distribution channel, the global xerostomia therapeutics market can be segmented into retail pharmacies, hospital pharmacies, and online pharmacies. In terms of regional analysis, North America region detained the prominent market share of around 40% among other regions such as Asia Pacific, Europe, Latin America, and Middle East & Africa in the global xerostomia therapeutics market.

Contact US:

Analytics Market Research

99 WALL STREET, #2124 NEW YORK, NY 10005

Phone: +1(650)-666-4592